Business Wire

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

Share

Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agreement for a novel investigational non-hormonal, on-demand contraceptive candidate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005145/en/

“As a leader in contraception, we believe it is critically important to bring forward new options for women, especially in the space of non-hormonal contraceptives, a category preferred by many with limited available options,” said Sandra Milligan, M.D., Organon’s head of Research and Development. “Organon is committed to driving innovation across women’s health and collaborating with companies like Cirqle Biomedical to support early science and bring forward new solutions that address the unmet needs of women.”

Encouraging preclinical research suggests that Cirqle has discovered a method that has the potential to create a temporary barrier to sperm transport by topically reinforcing the existing cervical mucus barrier.

“This collaboration is an important opportunity to advance our preclinical research exploring this asset’s first-in-class potential,” said Frederik Petursson Madsen, Cirqle Biomedical, CEO. “We are excited to join Organon to leverage Organon’s deep expertise in women’s and reproductive health to drive potential change for women who use contraception everywhere.”

Under the terms of the agreement, Cirqle will be responsible for conducting preclinical studies according to the mutually agreed research plan. Organon will obtain exclusive worldwide rights to develop and commercialize the asset. Cirqle is entitled to receive a $10 million upfront payment, potential milestone payments of up to $360 million and royalties based on net sales.

As stated on Organon’s first quarter conference call, to align with views expressed by the US Securities and Exchange Commission, beginning in 2022 Organon will no longer exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, from its non-GAAP results. Organon’s financial guidance does not assume an estimate for these expenses associated with business development not yet executed, and accordingly, the $10 million upfront payment was not included in the full year 2022 guidance Organon provided on May 5, 2022. Organon does not plan to update its guidance inter-quarter based solely on these items.

About Cirqle Biomedical

Cirqle Biomedical is a pre-clinical stage life science company with the goal of developing a first-in-class non-hormonal contraceptive that can help address the demand from millions of women for an effective contraceptive with minimal side-effects. Cirqle Biomedical’s approach to contraception is based on engineering mucus to leverage the natural barrier properties of cervical mucus. Cirqle Biomedical was launched in 2019 in Copenhagen, Denmark, with backing from BioInnovation Institute (BII) and Rhia Ventures, a San Francisco-based impact investor dedicated to women’s reproductive health. Cirqle Biomedical’s core ethos is to expand freedom and quality of life for women everywhere. We aim to solve the most prominent unmet medical needs in women’s health by developing groundbreaking user-centric innovations.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s research collaboration and exclusive license agreement with Cirqle Biomedical, the potential for Cirqle Biomedical’s program to produce a best-in-class non-hormonal, on-demand contraceptive, including the effectiveness of and market opportunity for Cirqle Biomedical’s investigational asset, and Organon’s goal of addressing the unmet needs of women. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Organon Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Edward Barger
(267) 614-4669

Cirqle Media Contacts:

Onor Wilkinson
ow@cirqle.bio

Cirqle Investor Contacts:

Frederik Petursson Madsen
fm@cirqle.bio

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Floyd Mayweather vs Deji to headline Global Titans Fight Night in Dubai26.9.2022 16:00:00 EEST | Press release

World-class boxing and entertainment company Global Titans announced that Dubai would play host to the first series of ‘Global Titans Fight Night’ . Exclusively broadcasting on PPV, this event looks to be a historic moment in the UAE sporting calendar due to its headline bout that pits the sports legend – Floyd Mayweather against the Gen-Z YouTube sensation turned pro-boxer Deji. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005387/en/ GLOBAL TITANS MAYWEATHER vs DEJI A3 (Photo: AETOSWire) This revamped epic boxing match will take place at the Coca-Cola Arena on the 13th of November, with a private weigh-in event on the 12th of November. Keeping in line with Global Titans' vision of bridging the world of music and sport, the event will see titans from the boxing world, and superstar entertainers meet to create an unforgettable spectacle that will be broadcasted to millions worldwide. The event will also launch the Glo

Omnichannel Customer Experience Leader Cindy Davis Joins Airship’s Board of Directors26.9.2022 16:00:00 EEST | Press release

Mobile app experience company Airship today announced the appointment of Cindy Davis to its Board of Directors. Davis brings decades of executive leadership experience driving stronger customer relationships through digital-first strategies for leading brands including Bed Bath & Beyond, L Brands, The Walt Disney Company, Walmart, Sam’s Club and more. Cindy is currently a board member of Destination Pet and serves on the Board of Trustees for William & Mary, Mason School of Business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005221/en/ Cindy Davis, a veteran executive leader of omnichannel customer experience for retail, hospitality and entertainment brands, joins Airship’s Board of Directors as an independent member. (Photo: Business Wire) Most recently, Davis was Chief Brand Officer for Bed Bath & Beyond where she modernized its digital and in-store customer experiences and drove key transformational strategies,

Hitachi Metals, Ltd.: Notice Concerning Change of Trade Name26.9.2022 15:30:00 EEST | Press release

Hitachi Metals, Ltd. (hereinafter, the “Company”) hereby announces that it has been resolved at today’s board of directors’ meeting that the Company’s trade name will be changed as follows. The above-stated change of trade name will be made on the condition that the takeover bid by K.K. BCJ-52 for which a public release was issued today is carried out successfully, and a subsequent range of procedures necessary for the change of the trade name, including partial revision of the Articles of Incorporation, are completed. New trade name Proterial, Ltd. Scheduled day of change of trade name January 4, 2023 Reasons for change of trade name The Company has its origin in Hitachi, Ltd., which was founded in 1910, and was spun off into an independent company in 1956. Since its original foundation, the Company has grown by providing the society with many unique products developed with its high technological capabilities. After a successful implementation of the Takeover Bid, the Company will acc

NTT Achieves World’s Fastest Zero-bias Operation of a Graphene Photodetector26.9.2022 15:00:00 EEST | Press release

NTT Corporation (“NTT”) and the National Institute for Materials Science (NIMS) have jointly achieved the world's fastest zero-bias operation1 (220 GHz) of a graphene photodetector (PD) 2. Furthermore, the research conducted by NTT and NIMS clarified the optical-to-electrical (O-E) conversion process in graphene for the first time. Graphene has high sensitivity and high-speed electrical response to a wide range of electromagnetic waves, from terahertz (THz) to ultraviolet (UV). Thus, it is a promising photodetection material for enabling high-speed O-E conversion at wavelength ranges where existing semiconductor devices cannot operate. However, until now, the demonstrated zero-bias operating speed has been limited to 70 GHz due to conventional device structure and measurement equipment. For this reason, the challenge for graphene PDs is to demonstrate 200-GHz operation speeds and clarify graphene's inherent properties, such the process of optical-to-electrical conversion. In this study

UC Berkeley Inclusive Data Program Inspires Learners From 30 Countries With the Power of Data & Analytics Using the Pyramid Decision Intelligence Platform26.9.2022 15:00:00 EEST | Press release

A 4-year public / private partnership between UC Berkeley Haas School of Business – Fisher Center for Business Analytics’ Program Director, Gauthier Vasseur, and Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today celebrated the milestone of teaching more than 2,000 learners in 30 countries. The Fisher Center’s Alliance for Inclusive AI (AIAI) program provides data & analytics workshops to improve inclusivity and accessibility to analytics. The Step Into Data program uses a combination of in-person and remote learning to reach people who are under-represented in AI, machine learning, and data analytics. The program will soon expand to the Netherlands, France, Georgia, India, and to new locations across the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005099/en/ “It is my pleasure to work with Pyramid Analytics... They are a company genuinely committed to improving a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom